









Markets
/
Stocks
/
nasdaq-nvs
/

Novartis AG

NVS

View Detailed Chart

119.450USD

-1.319-1.09%

Close 06/13, 16:00（ET）Quotes delayed by 15 min

234.03BMarket Cap

19.60P/E TTM



Novartis AG

119.450

-1.319-1.09%

Company

Intraday

30m

Today

-1.09%

5 Days

+1.21%

1 Month

+13.77%

6 Months

+21.44%

Year to Date

+22.75%

1 Year

+12.99%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 10 analysts

HOLD

Current Rating

111.948

Target Price

-6.28%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

167

Total

Median

Average

Company name

Ratings

Analysts

Novartis AG

NVS

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(2)

Neutral(3)

Buy(7)

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.872

Buy

RSI(14)

65.348

Neutral

STOCH(KDJ)(9,3,3)

83.271

Neutral

ATR(14)

1.554

High Vlolatility

CCI(14)

93.296

Neutral

Williams %R

14.909

Overbought

TRIX(12,20)

0.313

Sell

StochRSI(14)

0.860

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

118.978

Buy

MA10

118.028

Buy

MA20

115.216

Buy

MA50

111.716

Buy

MA100

110.102

Buy

MA200

109.138

Buy

News

NFL signs Novartis as first pharmaceutical partner-source

NEW YORK, March 13 (Reuters) - The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis NOVN.S, a league source told Reuters on Thursday.

ReutersThu, Mar 13

US appeals court lifts pause on generic version of Novartis' Entresto

WASHINGTON, Jan 16 - Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' NOVN.S blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary pause on MSN's launch.

ReutersThu, Jan 16

Company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Ticker SymbolNVS

CompanyNovartis AG

CEODr. Vasant (Vas) Narasimhan, M.D.

Websitehttps://www.novartis.com/